Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

Related Posts

GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes

Ramsey DJ, Makwana B, Dani SS, Patel M, Panchal K, Shah J, Khadke S, Kumar A, Patel T, Kosiborod MN, Fonarow GC, Ramsey KM, Nohria[...]

Use of CT-derived non-cardiovascular calcification marker for predicting cardiovascular events among diabetic older adults: the multi-ethnic study of atherosclerosis

Ghotbi E, Bluemke DA, Hathaway QA, Klein JG, Shabani M, Akhtarkhavari S, Barr RG, Bancks MP, Post WS, Budoff M, Lima JAC, Demehri S. Use[...]

Regulating the Cell Differentiation Trajectory of Progenitor Cells in Adipose Tissue Fibrosis

Zhang L, Cai X, Wu X, Jing Z, Zhao Y, Yao Y, Boström KI. Regulating the Cell Differentiation Trajectory of Progenitor Cells in Adipose Tissue[...]